Theravance Biopharma's financial profile has been fundamentally altered by the Trelegy royalty monetization, which injected substantial cash and enabled deleveraging, yet the underlying operational performance remains challenged by volatile YUPELRI revenue and...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.11-251.7% vs $0.07 | $21M-7.8% vs $22M |
Q2 2026 May 7, 2026 | -$0.10-443.6% vs $0.03 | $18M-0.5% vs $18M |
Q2 2026 Mar 19, 2026 | $0.06-86.4% vs $0.44 | $46M-18.9% vs $57M |
Q4 2025 Nov 10, 2025 | $0.04+133.3% vs -$0.12 | $20M+0.1% vs $20M |
Shares of Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report) saw strong trading volume on Tuesday. 769,058 shares were traded during mid-day trading, an increase of 39% from the previous session's volume of 554,398 shares.The stock last traded at $17.0450 and had previously closed at $17.05. Wall Street Analyst Weigh In TBPH has been
Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report) SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the completion of the sale, the senior vice president directly owned 213,476 shares in
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $16.95 and traded as high as $17.10. Theravance Biopharma shares last traded at $17.06, with a volume of 251,659 shares changing hands. Analyst Upgrades and Downgrades
Benchmark TBPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Theravance Biopharma Inc (TBPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.03 | $882.64M | 8.27 | 66.92% | 98.54% | 44.85% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $14.26 | $1.97B | -1.39 | -2.75% | -41.85% | -55.97% | — | |
| $42.38 | $2.46B | -62.32 | 8.63% | -13.23% | -10.42% | — | |
| $25.21 | $991.64M | 157.56 | 3.63% | 1.96% | 2.13% | — | |
| $111.12 | $24.09B | -17.34 | 66.73% | -76.94% | -111.26% | — |
Theravance Biopharma Inc (TBPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Theravance Biopharma Inc (TBPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Jun 29, 2026·SEC
Jun 23, 2026·SEC
Get notified when TBPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Theravance Biopharma Inc (TBPH) stock FAQ — growth, dividends, profitability & financials explained
Theravance Biopharma Inc (TBPH) reported $104.3M in revenue for fiscal year 2025. This represents a 602% increase from $14.9M in 2011.
Theravance Biopharma Inc (TBPH) grew revenue by 66.9% over the past year. This is strong growth.
Yes, Theravance Biopharma Inc (TBPH) is profitable, generating $53.8M in net income for fiscal year 2025 (98.5% net margin).
Theravance Biopharma Inc (TBPH) has a return on equity (ROE) of 44.8%. This is excellent, indicating efficient use of shareholder capital.
Theravance Biopharma Inc (TBPH) generated $51.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
